In this series, recognized experts from the University of Colorado's Severe Asthma Clinic and Comprehensive Lung and Breathing Program explain the implications of recently approved monoclonal antibodies for the treatment of severe eosinophilic asthma. They explain the value of recognizing the heterogeneity of asthma and the need for correct diagnosis of this troubling subtype as early as possible. Although new and emerging therapies show a promising reduction in disease burden, specialists say that equity and access issues still thwart their efforts to provide these benefits to every patient.
13001 East 17th Place
Aurora, CO 80045